ProMetic Life Sciences’ lead candidate, PBI-4050, has successfully completed the required GLP toxicology studies performed by a certified CRO confirming that it is safe to advance into clinical trial stages. Preclinical data on PBI-4050 confirms its potential as a novel therapy to inhibit inflammation and fibrosis which underlies progressive chronic renal diseases and pulmonary fibrosis, as well as fibrosis in other organs such as the liver and the heart. The company plans to commence Pha...